Tearsheet

MBX Biosciences (MBX)

Market Price (12/5/2025): $30.53 | Market Cap: $1.0 Bil
Sector: Health Care | Industry: Biotechnology

MBX Biosciences (MBX)

Market Price (12/5/2025): $30.53
Market Cap: $1.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -65%	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.		Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -91 Mil
2			Stock price has recently run up significantly 6M Rtn6 month market price return is 158%
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18%
4			High stock price volatility Vol 12M is 139%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -65%
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
2	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
3	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -91 Mil
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 158%
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18%
7	High stock price volatility Vol 12M is 139%

Valuation, Metrics & Events

	12/5/25	2024	2023	2022
Share Price CYE	$30.53	$18.43
Market Cap CYE ($ Bil)	1.0	0.6	-	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.4	0.3	0.1	0.0
Enterprise Value ($ Bil)	0.7	0.6
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0
P/EBIT TTM	-6.6	-2.9	0.0	0.0
P/E TTM	-7.4	-3.2	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9	4.4
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.2
P/E TTM (Sector)	-1.6	-1.5	-1.5	-1.3

	12/5/25	2024	2023
Share Price CYE	$30.53	$18.43
Market Cap CYE ($ Bil)	1.0	0.6	-
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.4	0.3	0.1
Enterprise Value ($ Bil)	0.7	0.6
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	-6.6	-2.9	0.0
P/E TTM	-7.4	-3.2	0.0
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.6	-1.5	-1.5

null

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Drug Pipeline - Canvuparatide (MBX 2109) Clinical Phase	Phase 2 trial completed, Phase 3 trial initiation planned for 2026	9222025	Link
Drug Pipeline - Imapextide (MBX 1416) Clinical Phase	Phase 2	10292025	Link
Drug Pipeline - MBX 4291 Clinical Phase	Phase 1	10292025	Link
Phase 2 Avail™ Trial (Canvuparatide) Enrollment	64	5122025	Link
Phase 2 Avail™ Trial (Canvuparatide) Responder Rate at 12 Weeks	63%	9222025	Link
Phase 1 Trial (MBX 1416) Enrollment	69	1072025	Link
Number of Employees	46	1012025	Link

Recent
11/06/2025	Earnings Release	Rev: - EPS: -
Upcoming
3/16/2026	Earnings Release	Rev: - EPS: -

MBX Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Here are the key points for why MBX Biosciences (MBX) stock moved by approximately 102% for the period from August 31, 2025, to December 5, 2025: 1. Positive Phase 2 Clinical Trial Results.

MBX Biosciences reported positive Phase 2 topline results in Q3 2025 for its lead product candidate, once-weekly canvuparatide, in patients with chronic hypoparathyroidism. The trial achieved its primary endpoint with a 63% responder rate at 12 weeks compared to 31% for placebo, and demonstrated a 79% responder rate at six months in the open-label extension. This significant clinical success likely fueled investor confidence in the company's pipeline. 2. Strong Financial Position Through Successful Public Offering.

In the third quarter of 2025, MBX Biosciences completed an upsized public offering, raising approximately $200 million. This offering strengthened the company's financial reserves to $391.7 million in cash and equivalents as of September 30, 2025, with management expecting this capital to fund operations into 2029. This extended cash runway reduces financial risk and supports ongoing and future development programs. 3. Overwhelmingly Positive Analyst Sentiment and Price Targets.

Following the positive clinical data, MBX Biosciences garnered significant attention from various analyst firms, with multiple "Buy" ratings and high price targets. By late November 2025, analysts had set an average price target of $64.43, suggesting a potential upside of 90.50% from the then-current price, indicating strong market optimism. 4. Advancement of Diverse Pipeline Candidates.

Beyond its lead candidate, MBX Biosciences continued to advance other promising therapies. The company is progressing MBX 1416 as a potential treatment for post-bariatric hypoglycemia and MBX 4291 for obesity and related co-morbidities. This diversified pipeline of novel precision peptide therapies for endocrine and metabolic disorders contributes to the company's long-term growth potential and investor interest. 5. Significant Insider Buying Activity.

In the three months leading up to December 2025, MBX Biosciences insiders showed strong confidence in the company by purchasing $12,537,788.00 worth of company stock, with no insider selling reported during the same period. This substantial insider buying, exceeding the $5 million threshold, signals a positive outlook from those closest to the company's operations and prospects.

Show less

Stock Movement Drivers

Fundamental Drivers

The 136.4% change in MBX stock from 9/4/2025 to 12/4/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	9042025	12042025	Change
Stock Price ($)	12.92	30.54	136.38%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	33.45	34.20	-2.25%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

9/4/2025 to 12/4/2025

	Return	Correlation
MBX	136.4%
Market (SPY)	5.4%	13.2%
Sector (XLV)	12.0%	-2.8%

Fundamental Drivers

The 157.5% change in MBX stock from 6/5/2025 to 12/4/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	6052025	12042025	Change
Stock Price ($)	11.86	30.54	157.50%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	0.00	�
P/S Multiple	�	∞	�
Shares Outstanding (Mil)	31.85	34.20	-7.36%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

6/5/2025 to 12/4/2025

	Return	Correlation
MBX	157.5%
Market (SPY)	15.7%	12.8%
Sector (XLV)	16.2%	9.2%

Fundamental Drivers

The 58.7% change in MBX stock from 12/4/2024 to 12/4/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	12042024	12042025	Change
Stock Price ($)	19.24	30.54	58.73%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	0.00	�
P/S Multiple	�	∞	�
Shares Outstanding (Mil)	31.85	34.20	-7.36%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2024 to 12/4/2025

	Return	Correlation
MBX	58.7%
Market (SPY)	13.7%	21.9%
Sector (XLV)	6.3%	16.7%

Fundamental Drivers

null
null

Market Drivers

12/5/2023 to 12/4/2025

	Return	Correlation
MBX
Market (SPY)	53.3%	21.0%
Sector (XLV)	20.1%	17.6%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
MBX Return	-	-	-	-	-	66%	66%
Peers Return	2%	-1%	6%	8%	-0%	3%	18%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	112%
Monthly Win Rates [3]
MBX Win Rate	-	-	-	-	0%	60%
Peers Win Rate	13%	8%	13%	12%	10%	90%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
MBX Max Drawdown	-	-	-	-	-	-69%
Peers Max Drawdown	-2%	-5%	0%	-0%	-1%	-2%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, AIXC, ALPS, BBOT, EVMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)

How Low Can It Go

MBX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About MBX Biosciences (MBX)

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include: • MBX 2109: Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the concentration of active drug observed immediately prior to the next dose, or peak-to-trough ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. • MBX 1416: We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide-1, or GLP-1, receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase 1 clinical trial, preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. • Obesity portfolio: Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptor co-agonist prodrug with the goal of reducing dosing frequency and improving efficacy and tolerability relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly GLP-1/GIP co-agonist, and an extended duration of action of the active component of MBX 4291, supporting the potential for once-monthly administration. During our preclinical studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in IND-enabling studies with an anticipated investigational new drug, or IND, submission in the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development. Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic peptides often have significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours by the liver and kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target selectivity, 3) half-lives that allow for dosing at weekly or less frequent intervals, and 4) low or flat peak-to-trough ratios to improve tolerability, thereby facilitating higher dosing and greater potential efficacy. We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana.

AI Generated Analysis | Feedback

A smaller, earlier-stage Eli Lilly focused on developing novel therapies for diabetes and related metabolic diseases.

Like a nascent Novo Nordisk, specializing in the research and development of new drugs for diabetes and liver conditions like MASH.

AI Generated Analysis | Feedback

Therapeutic Biologics: Novel biological drugs, such as monoclonal antibodies or gene therapies, developed to treat a range of human diseases.
Molecular Diagnostics: Advanced kits and platforms used for precise disease detection, patient stratification, and monitoring treatment response.
Research Reagents & Tools: Specialized biochemicals, antibodies, cell lines, and laboratory equipment supplied for life science research and development.

AI Generated Analysis | Feedback

MBX Biosciences (symbol: MBX), as a company operating in the biosciences sector, typically sells its products and services primarily to other companies and institutions rather than directly to individuals. Due to the confidential nature of client relationships in this industry, specific customer names are generally not publicly disclosed unless they represent major collaborations, licensing agreements, or acquisitions.

Based on the typical business model for a public biosciences company, MBX Biosciences' major customer categories would include:

Pharmaceutical Companies: These are often the primary customers for advanced therapeutics, novel drug candidates (through licensing or co-development agreements), specialized biologics, or platform technologies developed by biosciences firms. Major public pharmaceutical companies include (but are not limited to) Pfizer (PFE), Johnson & Johnson (JNJ), Merck & Co. (MRK), Novartis (NVS), and Bristol Myers Squibb (BMY).
Other Biotechnology Companies: This category encompasses a wide range of companies, from large established biotech firms to smaller, emerging ones. They may purchase specialized reagents, assays, research tools, or license specific technologies from MBX Biosciences to enhance their own research and development pipelines or product portfolios. Examples of public biotech companies include Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB).
Academic and Clinical Research Institutions: Universities, government laboratories, and major hospitals frequently serve as customers for biosciences companies. They purchase advanced research reagents, specialized diagnostic kits (if MBX produces them), or contract research services to support scientific discovery, clinical trials, and patient care.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Kent Hawryluk, President & CEO

Kent Hawryluk is a Co-Founder of, and currently serves as President and Chief Executive Officer of, MBX Biosciences, Inc. (Nasdaq: MBX), roles he has held since January 2020. He also has served as a member of MBX's Board of Directors since April 2019. Prior to joining MBX, Mr. Hawryluk was Co-Founder and Chief Business Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), an RNA therapeutics company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia was acquired by Roche in December 2010. Since January 2003, he has also served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund.

Richard Bartram, CPA, Chief Financial Officer

Richard Bartram has served as MBX's Chief Financial Officer since April 2022. Prior to joining MBX, Mr. Bartram served as Chief Financial Officer at Esperion Therapeutics, Inc., (Nasdaq: ESPR), a pharmaceutical company, from January 2018 to April 2022. During his tenure at Esperion, he led the company’s efforts to raise over $1.2 billion in capital, supporting the approval and commercialization of NEXLETOL® and NEXLIZET®. He also provided key contributions to several successful business development licensing transactions. Prior to Esperion, Mr. Bartram served as an assurance manager with PricewaterhouseCoopers LLP from 2005 to 2013. Mr. Bartram has an extensive understanding of capital markets and experience in private transactions, initial public offerings, and debt offerings.

Sam Azoulay, MD, Chief Medical Officer

Salomon (Sam) Azoulay, MD, has served as MBX's Chief Medical Officer since June 2024. He is an accomplished physician-scientist with over 35 years of experience in global drug development and operations. Prior to MBX, Dr. Azoulay served as Consulting Chief Executive Officer of Nervosave Therapeutics, a developer of gene therapies, from September 2023 to June 2024. Before that, Dr. Azoulay served as Chief Medical Officer at Sumitovant Biopharma Ltd., an independent subsidiary of Sumitomo Pharma Co. Ltd., from January 2021 to July 2023. He also previously served as Chief Medical Officer of Roivant from May 2018 to December 2020.

Michelle Graham, Chief Human Resources Officer

Chatan Charan, PhD, Sr. Vice President, Pharmaceutical Development and CMC

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

MBX Biosciences Addressable Markets

null

AI Generated Analysis | Feedback

MBX Biosciences (MBX) is poised for potential future revenue growth, primarily driven by the advancement and commercialization of its precision peptide therapies. Over the next 2-3 years, the key drivers of revenue growth are expected to include:

Commercialization of Canvuparatide (MBX 2109) for Chronic Hypoparathyroidism: Canvuparatide is MBX's lead product candidate, having demonstrated promising efficacy in Phase 2 trials with a potential best-in-class profile due to its weekly dosing. Analysts anticipate that its successful progression through Phase 3 trials and subsequent market launch could lead to peak sales exceeding $2 billion.
Advancement and Potential Commercialization of Imapextide (MBX 1416) for Post-Bariatric Hypoglycemia (PBH): Imapextide is currently in Phase 2 clinical evaluation. This investigational therapy is designed to prevent severe hypoglycemia in individuals with PBH and is considered another potential "billion-dollar opportunity" for the company.
Development and Potential Commercialization of MBX 4291 for Obesity: MBX 4291 is in Phase 1 clinical evaluation as a potential treatment for obesity. Analysts also view this candidate as a significant revenue opportunity, with potential for monthly GLP/GIP dosing.
Expansion of the Pipeline through the Proprietary PEP™ Platform Technology: MBX Biosciences leverages its proprietary Precision Endocrine Peptide (PEP™) platform to discover and develop new therapeutic candidates for endocrine and metabolic disorders. This platform underpins a growing pipeline, offering the potential for additional product launches beyond current lead candidates.
Strategic Collaborations and Partnerships: MBX Biosciences has opportunities to form strategic partnerships and licensing agreements. Such collaborations could accelerate the development and commercialization of its product candidates by providing additional resources, expertise, and access to established distribution networks, thereby significantly impacting future revenue.

AI Generated Analysis | Feedback

Share Issuance

In September 2025, MBX Biosciences completed an upsized public offering of 11,108,055 shares at $18.00 per share, generating approximately $199.9 million in gross proceeds.
The net proceeds from this September 2025 offering were $187.4 million.

Inbound Investments

MBX Biosciences has raised a total of $216 million in funding across four rounds.
The company's latest funding round was a Series C, completed on August 5, 2024, which raised $63.5 million.
Five investors participated in the Series C round, with Deep Track Capital leading, and Driehaus, Frazier Life Sciences, Orbimed, and Wellington also participating.

Capital Expenditures

Capital expenditures were reported as $0.87 million for the nine months ended September 30, 2025, and $0.87 million for the full year 2024.
The company reported capital expenditures of $0.13 million in 2023 and $0.44 million in 2022.
These expenditures likely support the company's focus on the discovery and development of precision peptide therapies for endocrine and metabolic disorders.

Better Bets than MBX Biosciences (MBX)

	MBX	Better Performance than MBX
Metric	Value	INDUSTRY: Biotechnology
Total Yield	-13.5%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), VRTX (3.7%), ABBV (3.4%)
P/Op Inc	-6.6

	MBX	Better Performance than MBX
Metric	Value	SECTOR: Health Care
Total Yield	-13.5%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/Op Inc	-6.6

	MBX	Better Performance than MBX
Metric	Value	ALL OTHER SECTORS
Total Yield	-13.5%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/Op Inc	-6.6

		Best Bets In Health Care Sector
	MBX	RPRX	HALO	DOCS	UTHR	CPRX	HRMY	LGND	ISRG	GMED	MD
What You Pay
P/E	-7.4	19.9	14.4	54.3	14.4	11.1	8.5	71.4	58.1	18.2	8.7
P/EBIT	-6.6	9.6	11.3	55.6	10.9	9.3	6.5	51.9	56.6	17.8	5.9
What You Get
Rev Chg Q	�	7.9%	22.1%	23.2%	6.8%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%
Rev Chg LTM	�	3.7%	31.2%	20.2%	13.5%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%
Rev Chg 3Y Avg	�	1.5%	29.0%	17.4%	19.0%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%
FCF/Rev 3Y Avg	�	115.2%	45.0%	42.7%	34.3%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Day 7 of Gains Streak for MBX Biosciences Stock with 49% Return (vs. 19% YTD) [10/31/2025]	Notification

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to MBX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
LXP	LXP Industrial Trust	2.8	406.1%	25.7%
OLMA	Olema Pharmaceuticals	2.4	237.1%	374.1%
COGT	Cogent Biosciences	5.4	178.2%	404.0%
CDTX	Cidara Therapeutics	5.9	119.6%	720.3%
SGML	Sigma Lithium	1.1	113.2%	-11.1%
IRWD	Ironwood Pharmaceuticals	0.6	99.5%	-15.8%
ALMS	Alumis	0.6	82.4%	5.6%
NPCE	NeuroPace	0.6	80.5%	51.7%
BW	Babcock & Wilcox Enterprises	0.7	80.5%	311.6%
CBLL	CeriBell	0.7	75.4%	-26.0%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CCOI	Cogent Communications	0.9	-53.0%	-74.0%
UP	Wheels Up Experience	0.5	-48.0%	-60.0%
TLRY	Tilray Brands	7.7	-41.8%	-45.7%
AMSC	American Superconductor	1.4	-41.4%	34.0%
CTEV	Claritev	0.6	-41.2%
BTDR	Bitdeer Technologies	2.5	-40.7%	-41.6%
FRMI	Fermi	11.1	-40.2%
JANX	Janux Therapeutics	1.0	-39.3%	-69.4%
ARDT	Ardent Health	1.2	-39.1%	-48.1%
SMR	NuScale Power	3.4	-35.9%	27.4%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

Peer Comparisons for MBX Biosciences

Peers to compare with:

Financials

	MBX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	MBX Bios.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Price	30.54	457.36	2.63	1.17	11.54	21.93	16.73
Mkt Cap	1.0	116.9	-	-	-	-	59.0
Rev LTM	0	11,723	0	-	0	10	0
Op Inc LTM	-91	-92	-5	-	-93	-70	-91
FCF LTM	-79	3,337	-6	-	-60	-64	-60
FCF 3Y Avg	-	2,064	-10	-	-	-	1,027
CFO LTM	-78	3,718	-6	-	-60	-64	-60
CFO 3Y Avg	-	2,419	-10	-	-	-	1,204

Growth & Margins

	MBX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	MBX Bios.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Rev Chg LTM	-	10.3%	-	-	-	-	10.3%
Rev Chg 3Y Avg	-	10.5%	-	-	-	-	10.5%
Rev Chg Q	-	11.0%	-	-	-	-	11.0%
QoQ Delta Rev Chg LTM	-	2.7%	-	-	-	-	2.7%
Op Mgn LTM	-	-0.8%	-	-	-	-700.7%	-350.7%
Op Mgn 3Y Avg	-	26.2%	-	-	-	-	26.2%
QoQ Delta Op Mgn LTM	-	1.0%	-	-	-	-	1.0%
CFO/Rev LTM	-	31.7%	-	-	-	-635.6%	-302.0%
CFO/Rev 3Y Avg	-	23.1%	-	-	-	-	23.1%
FCF/Rev LTM	-	28.5%	-	-	-	-636.5%	-304.0%
FCF/Rev 3Y Avg	-	19.8%	-	-	-	-	19.8%

Valuation

	MBX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	MBX Bios.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Cap	1.0	116.9	-	-	-	-	59.0
P/S	-	8.5	-	-	-	-	8.5
P/EBIT	-6.6	22.4	-	-	-	-	7.9
P/E	-7.4	27.2	-	-	-	-	9.9
P/CFO	-7.7	26.9	-	-	-	-	9.6
Total Yield	-13.5%	3.7%	-	-	-	-	-4.9%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.3%	-	-	-	-	2.3%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.7	-0.0	-	-	-	-	-0.3

Returns

	MBX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	MBX Bios.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
1M Rtn	48.1%	8.5%	-	23.2%	-4.6%	-	15.8%
3M Rtn	136.4%	15.2%	-	-	14.5%	-	15.2%
6M Rtn	157.5%	3.1%	-	-	-	-	80.3%
12M Rtn	58.7%	-1.4%	-	-	-	-	28.7%
3Y Rtn	-	44.0%	-	-	-	-	44.0%
1M Excs Rtn	46.8%	7.2%	-	22.0%	-5.9%	-	14.6%
3M Excs Rtn	158.6%	9.7%	-	-	10.8%	-	10.8%
6M Excs Rtn	142.1%	-12.4%	-	-	-	-	64.8%
12M Excs Rtn	47.3%	-15.2%	-	-	-	-	16.1%
3Y Excs Rtn	-	-28.7%	-	-	-	-	-28.7%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022
Filing Date	11/6/2025	3/17/2025	9/13/2024	9/13/2024
Key Financials
Total Revenue	0	0	0	0
EBITDA	-91	-68	-35	-26
Operating Income	-91	-68	-35	-25
Net Income	-80	-62	-33	-26
EPS	-2.39	-5.82	-1.02	-0.82
Growth Rates
Total Revenue Growth	-	-	-	-
EBITDA Growth	-52.7%	-93.3%	-36.8%	-
Operating Income Growth	-52.5%	-93.1%	-40.3%	-
Net Income Growth	-45.9%	-90.2%	-24.6%	-
Margins
EBITDA Margin	-	-	-	-
Operating Income Margin	-	-	-	-
Net Income Margin	-	-	-	-
Cash & Debt
Total Cash	392	262	81	42
Total Debt	1	0	0	0
Net Debt / (Cash)	-391	-262	-80	-42
Cash Flows
Net Cash from Operations	-78	-55	-32	-23
Free Cash from Operations	-79	-56	-32	-24
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023
Filing Date	11/6/2025	8/7/2025	5/12/2025	3/17/2025	11/7/2024	9/13/2024	5/12/2025	9/13/2024	11/7/2024
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0
Ebitda	-24	-22	-26	-19	-20	-17	-13	-10	-11
Operating Income	-24	-22	-27	-19	-20	-17	-13	-10	-11
Net Income	-22	-19	-24	-16	-18	-16	-12	-9	-10
EPS	-0.63	-0.58	-0.71	-0.47	-2.78	-0.50	-0.39	-0.28	-0.32
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	-	-	-
Ebitda TTM	-91	-86	-81	-68	-59	-51	-	-	-
Operating Income TTM	-91	-87	-81	-68	-60	-51	-	-	-
Net Income TTM	-80	-77	-73	-62	-55	-47	-	-	-
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-
EBITDA Growth	-22.2%	-31.0%	-99.4%	-86.5%	-79.2%	-	-	-	-
Operating Income Growth	-22.0%	-30.9%	-99.3%	-86.3%	-79.2%	-	-	-	-
Net Income Growth	-19.2%	-22.4%	-93.6%	-76.3%	-78.5%	-	-	-	-
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	392	225	241	262	277	55	-	81	-
Total Debt	1	1	0	0	0	0	0	0	0
Net Debt / (Cash)	-391	-224	-241	-262	-277	-55	-	-80	-
Cash Flows Quarterly
FCF from Operations	-22	-17	-23	-16	-15	-13	-11	-11	-8
Cash Flows TTM
FCF from Operations TTM	-78	-71	-67	-55	-50	-43	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-48.1%	-49.6%	-68.0%	-56.0%	-67.4%	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-45.7%	-49.2%	-52.1%	-51.3%	-51.2%	-	-	-	-

Price Behavior

Price Behavior

Market Price	$30.54
Market Cap ($ Bil)	1.0
First Trading Date	09/13/2024
Distance from 52W High	-11.5%
	50 Days	200 Days
DMA Price	$21.55	$18.25
DMA Trend	up	up
Distance from DMA	41.7%	67.4%
	3M	1YR
Volatility	217.8%	140.2%
Downside Capture	117.65	254.59
Upside Capture	507.11	271.13
Correlation (SPY)	12.1%	21.9%

MBX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.93	1.10	2.05	2.08	1.53	-0.34
Up Beta	2.56	1.50	0.29	0.71	0.92	-1.58
Down Beta	3.18	1.10	0.33	0.05	0.76	-0.16
Up Capture	448%	441%	715%	747%	778%	93%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	15	26	35	66	130	158
Down Capture	-229%	-104%	109%	184%	151%	101%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	5	15	27	58	117	143

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

null

Based On 5-Year Data

null

Based On 10-Year Data

null

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	4,629,382
Short Interest: % Change Since 10312025	1.0%
Average Daily Volume	750,881
Days-to-Cover Short Interest	6.17
Basic Shares Quantity	34,198,597
Short % of Basic Shares	13.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11062025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	5122025	10-Q 3/31/2025
12312024	3172025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
12312023	9132024	424B5 12/31/2023

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

MBX Biosciences (MBX)

Market Price (12/5/2025): $30.53 | Market Cap: $1.0 BilSector: Health Care | Industry: Biotechnology

MBX Biosciences (MBX)

Market Price (12/5/2025): $30.53Market Cap: $1.0 BilSector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

MBX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About MBX Biosciences (MBX)

Interactive Breakdown

Better Bets than MBX Biosciences (MBX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for MBX Biosciences

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/5/2025): $30.53 | Market Cap: $1.0 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/5/2025): $30.53
Market Cap: $1.0 Bil
Sector: Health Care
Industry: Biotechnology